Publication:
Prognostic factors in progressive high-grade glial tumors treated with systemic approach: A single center experience

Simple item page
dc.contributor.authorATASOY, BESTE MELEK
dc.contributor.authorsAlan, Ozkan; Telli, Tugba Akin; Tuylu, Tugba Basoglu; Arikan, Rukiye; Demircan, Nazim Can; Ercelep, Ozlem; Kaya, Serap; Babacan, Nalan Akgul; Atasoy, Beste M.; Bozkurt, Suheyla; Bayri, Yasar; Gul, Dilek; Ekinci, Gazanfer; Ziyal, Ibrahim; Dane, Faysal; Yumuk, P. Fulden
dc.date.accessioned2022-03-12T22:40:33Z
dc.date.available2022-03-12T22:40:33Z
dc.date.issued2021
dc.description.abstractPurpose Malignant high-grade gliomas are the most common and aggressive type of primary brain tumor, and the prognosis is generally extremely poor. In this retrospective study, we analyzed the outcome of systemic treatment in recurrent high-grade glioma patients and the impact of prognostic factors on survivals. Methods Data from 114 patients with recurrent high-grade glioma who received systemic treatment and followed in our clinic between 2012 and 2018 were retrospectively analyzed. Eastern Cooperative Oncology Group (ECOG) performance status, age, gender, histology, type of surgical resection, side effects after systemic treatment (deep vein thrombosis, hypertension, proteinuria), IDH1 and alpha thalassemia/mental retardation syndrome X-linked (ATRX) mutation status were investigated as prognostic factors for progression-free survival and overall survival. Results At the time of diagnosis, the median age was 48 (17-77) and 68% of the patients were male. Most common pathologic subtype was glioblastoma multiforme (68%). Median follow-up duration was 9.1 months (1-68 months). Median progression-free survival and overall survival were 6.2 months and 8 months, respectively. In multivariate analysis, ECOG PS, deep venous thrombosis and the presence of ATRX and IDH1 mutation were found to be independent prognostic factors for progression-free survival (p < 0.05) and, ECOG PS, the presence of ATRX and IDH1 mutation for overall survival (p < 0.05). Conclusion Our study is real life data and the median progression-free survival and overall survival rates are similar to the literature. We have found ECOG PS, presence of ATRX and IDH1 mutation to be independent prognostic factors for both progression-free survival and overall survival.
dc.identifier.doi10.1177/1078155220920684
dc.identifier.eissn1477-092X
dc.identifier.issn1078-1552
dc.identifier.pubmed32349641
dc.identifier.urihttps://hdl.handle.net/11424/235979
dc.identifier.wosWOS:000533010200001
dc.language.isoeng
dc.publisherSAGE PUBLICATIONS LTD
dc.relation.ispartofJOURNAL OF ONCOLOGY PHARMACY PRACTICE
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectHigh-grade gliomas
dc.subjectglioblastoma multiforme
dc.subjectATRX status
dc.subjectIDH status
dc.subjectthrombosis
dc.subjectBEVACIZUMAB-INDUCED HYPERTENSION
dc.subjectCENTRAL-NERVOUS-SYSTEM
dc.subjectVENOUS THROMBOEMBOLISM
dc.subjectADJUVANT TEMOZOLOMIDE
dc.subjectGLIOBLASTOMA
dc.subjectATRX
dc.subjectMUTATIONS
dc.subjectSURVIVAL
dc.subjectGLIOMA
dc.subjectIDH1
dc.titlePrognostic factors in progressive high-grade glial tumors treated with systemic approach: A single center experience
dc.typearticle
dspace.entity.typePublication
local.avesis.ida0207d43-6a66-483d-bb16-9bb19a505d5c
local.import.packageSS17
local.indexed.atWOS
local.indexed.atSCOPUS
local.indexed.atPUBMED
local.journal.articlenumber1078155220920680
local.journal.numberofpages11
local.journal.quartileQ4
oaire.citation.endPage339
oaire.citation.issue2
oaire.citation.startPage329
oaire.citation.titleJOURNAL OF ONCOLOGY PHARMACY PRACTICE
oaire.citation.volume27
relation.isAuthorOfPublication22ce1b48-93da-4e88-a61e-be24b5e6122a
relation.isAuthorOfPublication.latestForDiscovery22ce1b48-93da-4e88-a61e-be24b5e6122a

Files

Collections

Research Outputs